TEM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

12 Analyst Rating

Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 90.64 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

6 Hold

0 Sell

Moderate Buy

Current: 68.940

Low

80.00

Averages

90.64

High

105.00

Current: 68.940

Low

80.00

Averages

90.64

High

105.00

BTIG

Mark Massaro

Buy

maintain

$96 -> $105

2025-11-25

Reason

BTIG

Mark Massaro

Price Target

$96 -> $105

2025-11-25

maintain

Buy

Reason

BTIG analyst Mark Massaro raised the firm's price target on Tempus AI to $105 from $96 and keeps a Buy rating on the shares after meeting with its management team. Tempus AI outlined several durable growth drivers, namely that its data/pharma business is robust and diversified, Ambry's growth has tracked ahead of its deal model and is expected to grow over 20%, with rare disease testing as a complementary growth driver, and that its algo business might be a sleeper and could deliver over 80% gross margins with time, the analyst tells investors in a research note.

Morgan Stanley

NULL -> Overweight

upgrade

$68 -> $80

2025-11-11

Reason

Morgan Stanley

Price Target

$68 -> $80

2025-11-11

upgrade

NULL -> Overweight

Reason

Morgan Stanley raised the firm's price target on Tempus AI to $80 from $68 and keeps an Overweight rating on the shares.

Piper Sandler

Neutral

downgrade

$105 -> $80

2025-11-11

Reason

Piper Sandler

Price Target

$105 -> $80

2025-11-11

downgrade

Neutral

Reason

Piper Sandler lowered the firm's price target on Tempus AI to $80 from $105 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.

H.C. Wainwright

Yi Chen

Buy

downgrade

$98 -> $89

2025-11-07

Reason

H.C. Wainwright

Yi Chen

Price Target

$98 -> $89

2025-11-07

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Tempus AI to $89 from $98 and keeps a Buy rating on the shares post the Q3 report. The firm expects Tempus AI's sales growth in 2026 "to be healthy" at above 20%, but significantly less than the rate in 2025.

Canaccord

Kyle Mikson

Buy

downgrade

$110 -> $95

2025-11-05

Reason

Canaccord

Kyle Mikson

Price Target

$110 -> $95

2025-11-05

downgrade

Buy

Reason

Canaccord analyst Kyle Mikson lowered the firm's price target on Tempus AI to $95 from $110 and keeps a Buy rating on the shares. The firm said its target decrease is driven by lower revenue growth and operating margin expansion in the out years of their 10-year DCF model and noted the he company's Q3 performance was driven by solid execution across each of its business segments.

Piper Sandler

Overweight

maintain

$60 -> $90

2025-10-22

Reason

Piper Sandler

Price Target

$60 -> $90

2025-10-22

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Guardant Health to $90 from $60 and keeps an Overweight rating on the shares. The firm surveyed 59 oncologists to gauge their views on profiling and market share. Overall, Piper thinks the survey is positive for companies such as Guardant Health (GH) and Tempus AI (TEM). The firm sees liquid biopsy, where it believes Guardant has a first-mover advantage, as growing even faster than CGP, and saw significant interest in it among different use cases.

Valuation Metrics

The current forward P/E ratio for Tempus AI Inc (TEM.O) is -152.01, compared to its 5-year average forward P/E of -96.43. For a more detailed relative valuation and DCF analysis to assess Tempus AI Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-96.43

Current PE

-152.01

Overvalued PE

-41.39

Undervalued PE

-151.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

68.36

Current EV/EBITDA

278.30

Overvalued EV/EBITDA

1628.02

Undervalued EV/EBITDA

-1491.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.62

Current PS

8.42

Overvalued PS

10.25

Undervalued PS

7.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 884.13% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TEM News & Events

Events Timeline

No data

News

6.5

12-11Benzinga

Top 5 Stocks to Purchase and 5 to Divest in 2026

3.5

12-11NASDAQ.COM

Tempus AI's Strategic Initiative to Broaden Its Focus Beyond Cancer Care

6.0

11-26NASDAQ.COM

BTIG Upholds Buy Rating for Tempus AI (TEM)

People Also Watch

Frequently Asked Questions

What is Tempus AI Inc (TEM) stock price today?

The current price of TEM is 68.94 USD — it has decreased -2.37 % in the last trading day.

What is Tempus AI Inc (TEM)'s business?

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

What is the price predicton of TEM Stock?

What is Tempus AI Inc (TEM)'s revenue for the last quarter?

Tempus AI Inc revenue for the last quarter amounts to 334.21M USD, increased 84.72 % YoY.

What is Tempus AI Inc (TEM)'s earnings per share (EPS) for the last quarter?

Tempus AI Inc. EPS for the last quarter amounts to -0.46 USD, decreased -0.00 % YoY.

What changes have occurred in the market's expectations for Tempus AI Inc (TEM)'s fundamentals?

The market is revising Upward the revenue expectations for Tempus AI, Inc. (TEM) for FY2025, with the revenue forecasts being adjusted by 0.41% over the past three months. During the same period, the stock price has changed by -19.02%.

How many employees does Tempus AI Inc (TEM). have?

Tempus AI Inc (TEM) has 2400 emplpoyees as of December 15 2025.

What is Tempus AI Inc (TEM) market cap?

Today TEM has the market capitalization of 12.56B USD.